From prognostication to precision in acute myeloid leukemiaInvivoscribe Marketing2025-05-08T16:47:49-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications| Read more
Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and SwitzerlandInvivoscribe Marketing2025-03-28T10:05:45-07:00March 27th, 2025|2025 Press Releases, Press Releases| Read more
Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AMLInvivoscribe Marketing2024-12-18T09:49:08-08:00December 7th, 2024|2024 Videos, Featured Videos, Videos| Watch video
Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD AssessmentsInvivoscribe Marketing2024-10-01T16:51:20-07:00September 23rd, 2024|2024 Videos, Featured Videos, Videos| Watch video
Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALLInvivoscribe Marketing2024-09-25T09:19:32-07:00September 17th, 2024|2024 Videos, Featured Videos, Videos| Watch video
Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02Invivoscribe Marketing2024-09-25T10:07:41-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos| Watch video
Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01Invivoscribe Marketing2024-09-25T10:14:27-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos| Watch video
Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq SequencersInvivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications| Read more
Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AMLInvivoscribe Marketing2024-05-07T17:44:56-07:00May 8th, 2024|2024 Press Releases, Press Releases| Read more
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid LeukemiaInvivoscribe Marketing2024-05-02T11:47:00-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications| Read more
Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML AssessmentsInvivoscribe Marketing2024-04-01T16:59:27-07:00March 20th, 2024|2024 Videos, Featured Videos, Videos| Watch video
Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation SequencingInvivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications| Read more
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myelomaInvivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications| Read more
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell NeoplasmsInvivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications| Read more
The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AMLInvivoscribe Marketing2024-02-08T15:09:04-08:00November 16th, 2023|2023 Videos, Featured Videos, Videos| Watch video
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTAInvivoscribe Marketing2023-07-20T17:27:41-07:00July 21st, 2023|2023 Press Releases, Press Releases| Read more
MRD Applications and AnalysisInvivoscribe Marketing2023-07-11T18:20:48-07:00June 20th, 2023|2023 Videos, Featured Videos, Videos| Watch video
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer ResearchInvivoscribe Marketing2023-06-05T12:37:16-07:00June 2nd, 2023|2023 Press Releases, Press Releases| Read more
NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and PrimersInvivoscribe Marketing2023-06-06T16:30:52-07:00May 31st, 2023|2023 Videos, Featured Videos, Videos| Watch video
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in JapanInvivoscribe Marketing2023-05-25T17:09:22-07:00May 25th, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation AssayInvivoscribe Marketing2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases| Read more
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantInvivoscribe Marketing2024-08-02T14:22:45-07:00March 7th, 2023|2023 Publications, Featured Publications, Publications| Read more
Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD MonitoringInvivoscribe Marketing2023-03-09T08:51:36-08:00February 28th, 2023|2023 Videos, Featured Videos, Videos| Watch video
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in ChinaInvivoscribe Marketing2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases| Read more
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)Invivoscribe Marketing2023-02-01T21:02:16-08:00February 1st, 2023|2023 Press Releases, Press Releases| Read more